Cameron Turtle Aeglea Bio Therapeutics, Inc. (AGLE) insider trading activity

AGLE Quotes by TradingView

Cameron Turtle is Chief Executive Officer of Aeglea BioTherapeutics, Inc.. Currently has a direct ownership of 746,907 shares of AGLE, which is worth approximately $20.7 Million. The most recent transaction as insider was on Feb 15, 2024, when has been sold 400 shares (Common Stock) at a price of $9.82 per share, resulting in proceeds of $3,928. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 747K
0% 3M change
0.05% 12M change
Total Value Held $20.7 Million

Cameron Turtle Transaction History

Date Transaction Value Shares Traded Shares Held Form
Feb 15 2024
BUY
Grant, award, or other acquisition
$3,928 $9.82 p/Share
400 Added 0.05%
746,907 Common Stock
Nov 24 2023
BUY
Conversion of derivative security
-
723,440 Added 49.22%
746,507 Common Stock

Also insider at

BBIO
BridgeBio Pharma, Inc. Healthcare
Officer
EIDX
Eidos Therapeutics, Inc.
Chief Business Officer
CT

Cameron Turtle

Chief Executive Officer
San Francisco, CA

Track Institutional and Insider Activities on AGLE

Follow Aeglea BioTherapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells AGLE shares.

Notify only if

Insider Trading

Get notified when an Aeglea Bio Therapeutics, Inc. insider buys or sells AGLE shares.

Notify only if

News

Receive news related to Aeglea BioTherapeutics, Inc.

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on AGLE